Epiestriol Explained
Epiestriol (brand names Actriol, Arcagynil, Klimadoral), or epioestriol, also known as 16β-epiestriol or simply 16-epiestriol, as well as 16β-hydroxy-17β-estradiol, is a minor and weak endogenous estrogen, and the 16β-epimer of estriol (which is 16α-hydroxy-17β-estradiol).[1] [2] Epiestriol is (or has previously been) used clinically in the treatment of acne. In addition to its estrogenic actions, epiestriol has been found to possess significant anti-inflammatory properties without glycogenic activity or immunosuppressive effects, an interesting finding that is in contrast to conventional anti-inflammatory steroids such as hydrocortisone (a glucocorticoid).[3] [4]
Relative affinities (%) of epiestriol and related steroids[5] [6] [7] [8] Compound | | | | | | | |
---|
| 2.6 | 7.9 | 100 | 0.6 | 0.13 | 8.7 | <0.1 |
| <1 | <1 | 15 | <1 | <1 | ? | ? |
| <1 | <1 | 15 | <1 | <1 | ? | ? |
16β-Epiestriol | <1 | <1 | 20 | <1 | <1 | ? | ? |
| <1 | <1 | 31 | <1 | <1 | ? | ? |
Values are percentages (%). Reference ligands (100%) were progesterone for the, testosterone for the, for the, for the, aldosterone for the, for, and cortisol for . | |
See also
Notes and References
- Book: Elks J . The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. 14 November 2014. Springer. 978-1-4757-2085-3. 899–.
- Book: Labhart A . Clinical Endocrinology: Theory and Practice. 6 December 2012. Springer Science & Business Media. 978-3-642-96158-8. 522–.
- Latman NS, Kishore V, Bruot BC . 16-epiestriol: an anti-inflammatory steroid without glycogenic activity . Journal of Pharmaceutical Sciences . 83 . 6 . 874–7 . June 1994 . 9120824 . 10.1002/jps.2600830623 .
- Miller E, Bates R, Bjorndahl J, Allen D, Burgio D, Bouma C, Stoll J, Latman N . 16-Epiestriol, a novel anti-inflammatory nonglycogenic steroid, does not inhibit IFN-gamma production by murine splenocytes . Journal of Interferon & Cytokine Research . 18 . 11 . 921–5 . November 1998 . 9858313 . 10.1089/jir.1998.18.921 .
- Book: Raynaud JP, Ojasoo T, Bouton MM, Philibert D . Drug Design. Receptor Binding as a Tool in the Development of New Bioactive Steroids. 1979. 169–214. 10.1016/B978-0-12-060308-4.50010-X. 9780120603084. https://books.google.com/books?id=bhAlBQAAQBAJ&pg=PA169.
- Ojasoo T, Raynaud JP . Unique steroid congeners for receptor studies . Cancer Research . 38 . 11 Pt 2 . 4186–98 . November 1978 . 359134 .
- Ojasoo T, Delettré J, Mornon JP, Turpin-VanDycke C, Raynaud JP . Towards the mapping of the progesterone and androgen receptors . Journal of Steroid Biochemistry . 27 . 1–3 . 255–69 . 1987 . 3695484 . 10.1016/0022-4731(87)90317-7 .
- Raynaud JP, Bouton MM, Moguilewsky M, Ojasoo T, Philibert D, Beck G, Labrie F, Mornon JP . Steroid hormone receptors and pharmacology . Journal of Steroid Biochemistry . 12 . 143–57 . January 1980 . 7421203 . 10.1016/0022-4731(80)90264-2 .